Hoya releases clinical trial data for Miyosmart iQ

Hoya Vision Care and The Hong Kong Polytechnic University have released clinical trial results that suggest a new myopia control spectacle lens design could “halt clinically relevant myopia progression” for nine out of 10 children over the first year of wear.

Hoya has revealed the Miyosmart iQ, building on the defocus incorporated multiple segments (DIMS) Miyosmart lens design.

The new lens features defocus segments positioned closer to the geometric centre of the spectacle lenses, with the intention of continuously activating the near-peripheral retina – an area identified in studies as highly responsive to the myopic defocus signal.

The lens also has a higher defocus power and an extended treatment zone, delivering more extensive coverage of the child’s peripheral visual field even with larger frames.

Hoya Vision Care and The Hong Kong Polytechnic University presented the results of a randomised controlled clinical trial with the new lens at ARVO 2026 in Denver.

The trial involved 196 children in Hong Kong aged between four and 12 with myopia and showed that those who wore the Miyosmart iQ spectacle lenses showed no myopia progression, on average, at 12 months.

Axial elongation was below or comparable to emmetropes in children wearing Miyosmart iQ spectacle lenses.

The trial also marked the first time with DIMS technology-based spectacle lenses that myopia control efficacy was demonstrated in children as young as four.

12-month trial results

In children aged between four and 12 participating in the study, the mean change in spherical equivalent refractive error over a period of 12 months was +0.046D in the Miyosmart iQ group, compared to –0.534D for the single vision spectacle lens control group.

Mean change in axial length over a 12-month period was 0.075mm for the Miyosmart iQ group compared to 0.346mm for the single vision group.

The company said: “As such, Miyosmart iQ reduced excessive axial elongation to levels below or comparable to emmetropic eye growth.”

John Goltermann Lassen, CEO of Hoya Vision Care, commented: “This milestone is truly a generational leap in myopia control and represents an important step toward the vision we are committed to shaping for children around the world. Until today, no trial conducted on a myopia control spectacle lens has shown this level of effectiveness in controlling the condition.”

Efficacy across ages

In children with myopia between the ages of four and six, Miyosmart iQ demonstrated a myopia control efficacy of 65% spherical equivalent refractive error and 44% in axial length over a 12-month period.

In Miosmart iQ and single vision groups respectively, the mean changes in spherical equivalent refractive error were –0.220D and –0.635D, while mean changes in axial length were 0.266mm and 0.475mm.

Dr Natalia Vlasak, Hoya Vision Care’s global head of medical and scientific affairs, said: “Beyond stopping myopia progression on average over a period of 12 months and across childhood stages, these findings demonstrate – for the first time with myopia control spectacle lenses – efficacy in children from four years of age with early-onset myopia, enabling us to control it at a critical time when it is progressing rapidly and the risk of long-term impact is highest.”

For older children aged between seven and 12, the spectacle lens demonstrated myopia control efficacy of “over 100% in spherical equivalent refractive error and 94% in axial length over a 12-month period.”

The mean changes in the Miyosmart iQ group for spherical equivalent refractive error were +0.155D, compared to –0.511D in the single vision group, in axial length the change was 0.019mm and 0.310mm respectively.

Hoya Vision Care suggested children of all ages demonstrated a high level of compliance to daily, all-day wear of Miyosmart iQ.

Behind the release

Hoya Vision Care held a press conference on April 22 to introduce its new clinical trial results and the Miyosmart iQ, featuring experts from across Hoya, the Hong Kong Polytechnic University, and the field of myopia.

Kazuma Kozu, a research and development director at Hoya Vision Care, gave an insight into the journey of the DIMS technology and launch of Miyosmart in 2018.

He explained how the company sought to further enhance the efficacy of Miyosmart, and that a comprehensive review of the scientific literature supported the new design idea as the “near peripheral retina is highly sensitive to the myopic defocus signal.”

Dr Natalia Vlasak, global head of medical and scientific affairs at Hoya Vision Care, discussed what makes Miyosmart unique, from its defocus design, to the fact more than 100 publications show the performance of the spectacle lenses in different age groups, populations, and ethnicities.

She highlighted that research on Miyosmart is the longest clinical study on myopia control spectacle lenses running to-date.

Vlasak explained that there were several phases to testing the Miyosmart iQ spectacle lens, including initial tests to ensure the design was safe.

“What came out of the study is that children can accept, can adapt, and can wear the lenses, and there was no impact on visual function,” she said.

Professor Chi-ho To, visiting chair professor of experimental optometry at Hong Kong Polytechnic University and founding director and senior advisor of the Centre for Vision and Eye Research at the Hong Kong Science Park, outlined the Miyosmart iQ trial and 12-month results.

He explained that, when recruiting for the trial, researchers looked for children with early onset myopia, and amongst older children, for a demonstrated history of progressive myopia.

The study was divided into three groups: single vision, Miyosmart, and Miyosmart iQ.

He outlined that the key finding of the study was that in Miyosmart iQ wearers, there was no myopia progression across the average data from all the age groups in the first 12 months, and minimal eye growth on average.

Finally, the importance of myopia control was emphasised by Professor Serge Resnikoff, chair of the International Myopia Institute board, Our Children’s Vision advisory board chair, and president and chair of Organisation pour la Prévention de la Cécité.

Resnikoff highlighted that myopia is a global public health problem: “The consequences are the same everywhere in the world, because myopia has a very significant risk of retinal morbidity. The risk increases exponentially and there is no safe level.”

He emphasised that acting early is important, but noted that access to myopia management solutions is uneven.

Because of this, he said, system-level action is required to ensure children have access to screening, that products are appropriately regulated and made available and accessible.